AU2001296240A1 - Method for inhibiting cataracts - Google Patents

Method for inhibiting cataracts

Info

Publication number
AU2001296240A1
AU2001296240A1 AU2001296240A AU9624001A AU2001296240A1 AU 2001296240 A1 AU2001296240 A1 AU 2001296240A1 AU 2001296240 A AU2001296240 A AU 2001296240A AU 9624001 A AU9624001 A AU 9624001A AU 2001296240 A1 AU2001296240 A1 AU 2001296240A1
Authority
AU
Australia
Prior art keywords
group
cataracts
inhibiting
inhibiting cataracts
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296240A
Inventor
Pamela Wang Anderson
Andreas Sashegyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001296240A1 publication Critical patent/AU2001296240A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to a method for inhibiting cataracts comprising administering to a patient in need thereof an effective amount of a compound of the formula (I); or a pharmaceutical salt or solvate thereof wherein: R1 and R3 are independently hydrogen, methyl, benzoyl, substituted benzoyl, or C(O)-(C1-C6 alkyl); R2 is selected from the group pyrolidin-1-yl, piperidin-1-yl, and hexamethyleneimin-1-yl; where the R2 group is optionally the N-oxide.
AU2001296240A 2000-10-25 2001-10-12 Method for inhibiting cataracts Abandoned AU2001296240A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24310100P 2000-10-25 2000-10-25
US60/243,101 2000-10-25
US25380000P 2000-11-29 2000-11-29
US60/253,800 2000-11-29
PCT/US2001/027766 WO2002034266A1 (en) 2000-10-25 2001-10-12 Method for inhibiting cataracts

Publications (1)

Publication Number Publication Date
AU2001296240A1 true AU2001296240A1 (en) 2002-05-06

Family

ID=26935594

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296240A Abandoned AU2001296240A1 (en) 2000-10-25 2001-10-12 Method for inhibiting cataracts

Country Status (7)

Country Link
US (1) US20040087572A1 (en)
EP (1) EP1335727B1 (en)
AT (1) ATE278403T1 (en)
AU (1) AU2001296240A1 (en)
DE (1) DE60106293T2 (en)
ES (1) ES2228958T3 (en)
WO (1) WO2002034266A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112881A1 (en) * 2008-11-03 2010-05-06 Pradip Bahukudumbi Composite material and method for manufacturing composite material
WO2015122954A2 (en) * 2013-11-27 2015-08-20 Humanetics Corporation Protecting tissue and mitigating injury from chemical exposure
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451589A (en) * 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol

Also Published As

Publication number Publication date
DE60106293T2 (en) 2005-11-17
ATE278403T1 (en) 2004-10-15
WO2002034266A1 (en) 2002-05-02
EP1335727A1 (en) 2003-08-20
US20040087572A1 (en) 2004-05-06
DE60106293D1 (en) 2004-11-11
ES2228958T3 (en) 2005-04-16
WO2002034266A9 (en) 2002-08-15
EP1335727B1 (en) 2004-10-06
WO2002034266A8 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
WO2000021927A3 (en) Pyrrole-2,5-diones as gsk-3 inhibitors
DE60317326D1 (en) PHENYL ALKANIC ACID AND PHENYLOXYALKANIC DERIVATIVES AS HPPAR ACTIVATORE
GEP20033028B (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
RU94036772A (en) Application of 2-phenyl-3-aroylbenzothiophenes for endometriosis inhibition
RU94044436A (en) Method of suppression of skin and vagina atrophy
NO944927L (en) Method for inhibiting pulmonary hypertensive disease
PL1682528T3 (en) BENZO [b][1,4] DIOXEPINE DERIVATIVES
NO944914L (en) Method of inhibiting autoimmune diseases
WO2001012169A3 (en) Method of cancer treatment
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
MY132085A (en) Methods for inhibiting bone prosthesis degeneration
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AU2001296240A1 (en) Method for inhibiting cataracts
WO2000051589A3 (en) VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF
NZ517315A (en) New derivatives of A-500359
GB0019008D0 (en) Therapeutic compounds
NO944577L (en) Inhibition of the effect of amyloidogenic proteins
AP2001002314A0 (en) Substituted benzolactam compounds.
IL151167A0 (en) Pyrrolopyridazine derivatives and pharmaceutical compositions containing the same